C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/31 (2006.01) A61K 39/09 (2006.01) A61K 39/40 (2006.01) A61K 48/00 (2006.01) C07K 14/315 (2006.01) C07K 14/34 (2006.01) C07K 16/12 (2006.01) C12N 5/12 (2006.01) C12N 15/12 (2006.01) C12N 15/63 (2006.01) C12Q 1/68 (2006.01) G01N 33/53 (2006.01) A61K 39/00 (2006.01)
Patent
CA 2417357
This invention provides isolated nucleic acids encoding polypeptides comprising amino acid sequences of streptococcal matrix adhesion (Ema) polypeptides. The invention provides nucleic acids encoding Group B streptococcal Ema polypeptides EmaA, EmaB, EmaC, EmaD and EmaE. The present invention provides isolated polypeptides comprising amino acid sequences of Group B streptococcal polypeptides EmaA, EmaB, EmaC, EmaD and EmaE, including analogs, variants, mutants, derivatives and fragments thereof. Ema homologous polypeptides from additional bacterial species, including S. pneumoniae, S. pyogenes, E. faecalis and C. diptheriae are also provided. Antibodies to the Ema polypeptides and immunogenic fragments thereof are also provided. The present invention relates to the identification and prevention of infections by virulent forms of streptococci. This invention provides pharmaceutical compositions, immunogenic compositions, vaccines, and diagnostic and therapeutic methods of use of the isolated polypeptides, antibodies thereto, and nucleic acids. Assays for compounds which modulate the polypeptides of the present invention for use in therapy are also provided.
L'invention concerne des acides nucléiques isolés codant des polypeptides contenant des séquences d'acides aminés de polypeptides d'adhésion de matrice extracellulaire streptococciques (Ema). L'invention a trait à des acides nucléiques codant les polypeptides Ema streptococciques de groupe B : EmaA, EmaB, EmaC, EmaD et EmaE. Cette invention concerne des polypeptides isolés renfermant des séquences d'acides aminés de polypeptides streptococciques de groupe B : EmaA, EmaB, EmaC, EmaD et EmaE, y compris des analogues, des variants, des mutants, des dérivés et des fragments correspondants. Cette invention concerne des polypeptides homologues Ema provenant d'espèces bactériennes supplémentaires, notamment <i>S. pneumoniae, S. pyogenes, E. faecalis</i> <i>C. diptheriae</i>, ainsi que des anticorps aux polypeptides Ema et des fragments immunogénes correspondants. Cette invention porte aussi sur l'identification et la prévention d'infections par des formes virulentes de streptocoques. Ladite invention concerne, en outre, des compositions pharmaceutiques et immunogènes, des vaccins et des méthodes diagnostiques et thérapeutiques d'utilisation des polypeptides isolés, des anticorps correspondants et des acides nucléiques. Ladite invention concerne des dosages destinés à des composés qui modulent les polypeptides susmentionnés utilisés en thérapie.
Adderson Elisabeth
Bohnsack John
Borden Ladner Gervais Llp
St. Jude Children's Research Hospital
University Of Utah Research Foundation
LandOfFree
Group b streptococcus polypeptides nucleic acids and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Group b streptococcus polypeptides nucleic acids and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Group b streptococcus polypeptides nucleic acids and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1638178